NBTX Quote, Financials, Valuation and Earnings

DBV Technologies SA has a net margin of -- compared to Nanobiotix SA's net margin of --. Nanobiotix SA's return on equity of -- beat DBV Technologies SA's return on equity of --.

Nanobiotix SA has a consensus price target of $7.21, signalling upside risk potential of 116.51%. On the other hand DBV Technologies SA has an analysts' consensus of $22.63 which suggests that it could grow by 208.06%. Given that DBV Technologies SA has higher upside potential than Nanobiotix SA, analysts believe DBV Technologies SA is more attractive than Nanobiotix SA.

Nanobiotix SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -0.080, suggesting its less volatile than the S&P 500 by 108.034%.

Nanobiotix SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nanobiotix SA pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

Nanobiotix SA quarterly revenues are --, which are smaller than DBV Technologies SA quarterly revenues of --. Nanobiotix SA's net income of -- is lower than DBV Technologies SA's net income of -$23M. Notably, Nanobiotix SA's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nanobiotix SA is 3.98x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

Edap TMS SA has a net margin of -- compared to Nanobiotix SA's net margin of -9.55%. Nanobiotix SA's return on equity of -- beat Edap TMS SA's return on equity of -39.5%.

Nanobiotix SA has a consensus price target of $7.21, signalling upside risk potential of 116.51%. On the other hand Edap TMS SA has an analysts' consensus of $8.50 which suggests that it could grow by 498.59%. Given that Edap TMS SA has higher upside potential than Nanobiotix SA, analysts believe Edap TMS SA is more attractive than Nanobiotix SA.

Nanobiotix SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Edap TMS SA has a beta of 0.124, suggesting its less volatile than the S&P 500 by 87.615%.

Nanobiotix SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edap TMS SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nanobiotix SA pays -- of its earnings as a dividend. Edap TMS SA pays out -- of its earnings as a dividend.

Nanobiotix SA quarterly revenues are --, which are smaller than Edap TMS SA quarterly revenues of $21.7M. Nanobiotix SA's net income of -- is lower than Edap TMS SA's net income of -$2.1M. Notably, Nanobiotix SA's price-to-earnings ratio is -- while Edap TMS SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nanobiotix SA is 3.98x versus 0.76x for Edap TMS SA. Usually stocks with elevated PS ratios are considered overvalued.

Genfit SA has a net margin of -- compared to Nanobiotix SA's net margin of --. Nanobiotix SA's return on equity of -- beat Genfit SA's return on equity of --.

Nanobiotix SA has a consensus price target of $7.21, signalling upside risk potential of 116.51%. On the other hand Genfit SA has an analysts' consensus of $10.17 which suggests that it could grow by 210.63%. Given that Genfit SA has higher upside potential than Nanobiotix SA, analysts believe Genfit SA is more attractive than Nanobiotix SA.

Nanobiotix SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Genfit SA has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.243%.

Nanobiotix SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Genfit SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nanobiotix SA pays -- of its earnings as a dividend. Genfit SA pays out -- of its earnings as a dividend.

Nanobiotix SA quarterly revenues are --, which are smaller than Genfit SA quarterly revenues of --. Nanobiotix SA's net income of -- is lower than Genfit SA's net income of --. Notably, Nanobiotix SA's price-to-earnings ratio is -- while Genfit SA's PE ratio is 32.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nanobiotix SA is 3.98x versus 5.63x for Genfit SA. Usually stocks with elevated PS ratios are considered overvalued.

Sanofi SA has a net margin of -- compared to Nanobiotix SA's net margin of 6.54%. Nanobiotix SA's return on equity of -- beat Sanofi SA's return on equity of 7.55%.

Nanobiotix SA has a consensus price target of $7.21, signalling upside risk potential of 116.51%. On the other hand Sanofi SA has an analysts' consensus of $63.84 which suggests that it could grow by 23.96%. Given that Nanobiotix SA has higher upside potential than Sanofi SA, analysts believe Nanobiotix SA is more attractive than Sanofi SA.

Nanobiotix SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sanofi SA has a beta of 0.578, suggesting its less volatile than the S&P 500 by 42.246%.

Nanobiotix SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sanofi SA offers a yield of 7.65% to investors and pays a quarterly dividend of $2.04 per share. Nanobiotix SA pays -- of its earnings as a dividend. Sanofi SA pays out 84.6% of its earnings as a dividend. Sanofi SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Nanobiotix SA quarterly revenues are --, which are smaller than Sanofi SA quarterly revenues of $8.1B. Nanobiotix SA's net income of -- is lower than Sanofi SA's net income of $531.9M. Notably, Nanobiotix SA's price-to-earnings ratio is -- while Sanofi SA's PE ratio is 20.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nanobiotix SA is 3.98x versus 2.68x for Sanofi SA. Usually stocks with elevated PS ratios are considered overvalued.